Kamada (NASDAQ:KMDA) Earns Buy Rating from Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Kamada (NASDAQ:KMDA) in a research note issued on Friday. The firm set a “buy” rating on the biotechnology company’s stock.

Several other equities analysts also recently weighed in on KMDA. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Kamada in a research report on Thursday, May 9th. Stifel Nicolaus began coverage on Kamada in a research report on Wednesday. They set a “buy” rating and a $18.00 target price on the stock.

Kamada Stock Up 3.0 %

KMDA opened at $5.15 on Friday. The firm has a market cap of $296.02 million, a P/E ratio of 22.39 and a beta of 1.06. Kamada has a 52 week low of $4.08 and a 52 week high of $6.53. The business’s fifty day simple moving average is $5.26 and its 200 day simple moving average is $5.61.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). The company had revenue of $37.74 million for the quarter, compared to analyst estimates of $38.01 million. Kamada had a net margin of 8.33% and a return on equity of 5.50%. As a group, equities analysts expect that Kamada will post 0.26 EPS for the current fiscal year.

Hedge Funds Weigh In On Kamada

Several large investors have recently added to or reduced their stakes in KMDA. EWA LLC purchased a new position in shares of Kamada in the 4th quarter worth about $68,000. Calton & Associates Inc. purchased a new position in shares of Kamada in the 4th quarter worth about $111,000. Y.D. More Investments Ltd raised its holdings in shares of Kamada by 107.1% in the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 15,000 shares during the period. Aristides Capital LLC raised its holdings in shares of Kamada by 41.6% in the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 16,635 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Kamada by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after purchasing an additional 100,800 shares during the period. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.